LifeVantage is a debt-free, high-margin but shrinking wellness business whose upside depends on Moorehead-led consultant recovery, LoveBiome execution, and subscription retention.
Overview
LifeVantage Corporation (LFVN) sells premium nutrigenomic supplements and skincare through a direct-selling network spanning approximately 20 countries. The Americas generate 78.4% of revenue, Japan contributes roughly 11.0%, and approximately 70% of sales are recurring monthly autoship purchases. The portfolio combines Protandim cellular synergizers, TrueScience beauty products, MindBody metabolic products, and the newly acquired LoveBiome gut-health system. **The business remains structurally high margin and financially resilient, but its operating momentum is weak:** Q3 FY2026 revenue fell 25.2% year over year to $43.7 million, active accounts declined 22.1% to 109,000, and adjusted EBITDA dropped 50.0% to $3.2 million. Management expects FY2026 revenue near $185 million, adjusted EBITDA near $15 million, and adjusted EPS near $0.60, toward the low end of prior guidance. The investment case depends on CEO Terrence Moorehead’s August 2026 transition, Shopify conversion improvements, LoveBiome integration, and stabilization of consultant recruitment. At $6.20–$6.40, valuation is approximately 0.42x price-to-sales, with a debt-free balance sheet, $12.5 million of cash, an increased dividend, and a $60 million repurchase authorization providing support. However, the scenario range is unusually wide, from $1.84 to $23.55 over five years.